Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

A 13-year-old girl with various symptoms was successfully treated with an antibiotic called co-trimoxazole.

Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.

Cedrol promotes hair growth better than baricitinib by regulating immune cells.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

A new topical treatment for hair loss shows strong hair growth effects with low toxicity.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

AS101 reduces hair loss from chemotherapy.

JAK inhibitors can cause severe acne, limiting their use for hair regrowth.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Increasing COX-2 in mouse skin causes bigger sebaceous glands and thinner hair, but stopping COX-2 can reverse hair thinning.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

IND-Ca ointment effectively reduces inflammation with minimal skin irritation.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Combining immune checkpoint inhibitors with other cancer therapies increases skin side effects in Asian patients.